CSL Research Acceleration Initiative

Immunology

Immune deficiencies
Primary immune deficiency gene therapy and targets

Autoimmune diseases
(e.g. Primary Sjögren’s syndrome, systemic sclerosis, inflammatory idiopathic myopathies incl. dermatomyositis, autoimmune blistering diseases)

Therapeutic strategies for autoimmune diseases
• Novel immunomodulatory strategies targeting cytokines, chemokines, modulatory proteins and TNF family members
• B cell depletion / regulation strategies

Alternatives to plasma-derived immunoglobulin / Recombinant IVIg

Hematology

Hemorrhagic and acute ischemic stroke
• Novel biologic targets/therapeutics or strategies to understand pathomechanisms
• Biomarker/Omics approaches for patient stratification and drug discovery

Acute thrombosis (venous and arterial thrombosis)​
Novel therapies/approaches for targeted fibrinolysis/thrombolysis with increased efficacy and safety

Sickle cell disease
Prophylactic therapies to reduce vaso occlusive crises and chronic vasculopathy

Respiratory

Asthma
(severe, uncontrolled)

Chronic obstructive pulmonary disease
(exacerbations)

Non-cystic fibrosis bronchiectasis

Interstitial lung diseases
(progressive fibrosing)

Community acquired pneumonia (CAP)-associated complications
(acute respiratory distress syndrome, sepsis, acute kidney injury)

Cardiovascular & Metabolic

Myocarditis

Dilated cardiomyopathy
Inflammatory etiologies

Severe forms of atherosclerosis
Inflammatory targets/candidates

Rare lipid disorders
(e.g. homozygous familial hypercholesterolemia)

Transplant

Chronic lung allograft dysfunction
Including prevention, antibody mediated rejection, tolerance, immunomodulation, biomarkers, animal models

Hematopoietic stem cell transplant (HSCT)
Treatment and prevention of acute and chronic GvHD, tolerance, immunomodulation, improving efficacy / safety of HSCT

Cardiovascular allograft vasculopathy
Treatment and animal models

Ischemia reperfusion injury
Prevention

Vaccines

mRNA and lipid nanoparticle platform
Innovative research addressing improved delivery, formulation, stabilization (5 C / room temperature), shelf life extension and manufacturing technologies

Influenza virus antigen purity and yield enhancement
Innovative research with potential to impact yield and purity of influenza virus HA antigen produced in MDCK cell culture

Proven adjuvant technology
Partnerships with our proprietary adjuvant MF59®

Cell & Gene Therapy

• In vivo kill switch or suicide switch
  
• Modulation of transgene expression in vivo
  
• Novel methods to select gene modified HSCs
  
• Novel therapeutic gene therapy targets aligned with CSL’s Therapeutic Areas
  
• Non viral in vivo delivery of RNPs
  
• Alternative mRNA delivery methods

Plasma & Recombinant Technologies

• Oral delivery of biologics
  
• Protein purification technologies
  
• Bioprocess improvements
  
• MDCK cell culture yield improvements